Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vidutolimod
- Development stage
- Phase 3
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous, Intratumoral
01
Overview
Vidutolimod is a virus-like particle (VLP) composed of the Qbeta bacteriophage capsid encapsulating a toll-like receptor 9 (TLR9) agonist—specifically an unmethylated CpG-A oligodeoxynucleotide. It is designed to activate plasmacytoid dendritic cells (pDCs) via TLR9 stimulation within the tumor microenvironment. This activation leads to robust production of type I interferons and stimulates anti-tumor CD8+ T cell responses. Vidutolimod is being developed as an investigational cancer vaccine and immunotherapy for various solid tumors and lymphomas. Its mechanism involves both direct immune activation by the VLP and delivery of CpG-A to pDCs for enhanced immune response[1][4][5][6].
- Brand names
- Immunodrug CYT003-QbG10
- Other names
- CYT 003 QbetaG10CYT003 QbetaG10CYT-003 QbetaG10CYT003 PolQbCYT-003 PolQbCYT 003 PolQbCYT003 PolQbetaCYT-003 PolQbetaCYT 003 PolQbetaCYT003-QbG10CYT-003-QbG10CYT 003-QbG10
02
Targets
TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on vidutolimod.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vidutolimod.